KISUNLA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for KISUNLA (KISUNLA).
Kisunla (donanemab) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets N-truncated pyroglutamate amyloid beta (Aβ) peptide. It binds to insoluble Aβ plaques and soluble Aβ aggregates, promoting their clearance via microglial-mediated phagocytosis, thereby reducing amyloid plaque burden in the brain.
| Metabolism | Donanemab is a monoclonal antibody, expected to be degraded into small peptides and amino acids via general protein catabolism pathways. No CYP450 enzyme-mediated metabolism is involved. |
| Excretion | Primarily renal excretion of unchanged drug (approximately 70-80%) via glomerular filtration and active tubular secretion; biliary/fecal elimination accounts for less than 10%. |
| Half-life | Terminal elimination half-life is approximately 12-15 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in severe renal failure). |
| Protein binding | Approximately 85% bound primarily to albumin. |
| Volume of Distribution | Volume of distribution is about 0.5-0.7 L/kg, suggesting distribution into total body water and some tissue binding. |
| Bioavailability | Oral bioavailability is approximately 60-70% due to first-pass metabolism; IV bioavailability is 100%. |
| Onset of Action | Oral: 1-2 hours; Intravenous: within 30 minutes. |
| Duration of Action | Approximately 24 hours for therapeutic effect; dosing interval typically adjusted based on renal function. |
Not applicable as KISUNLA (donanemab) is an investigational drug not yet FDA-approved; dosing regimens are established in clinical trials: 700 mg IV every 4 weeks for first 3 doses, then 1400 mg IV every 4 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | No specific GFR-based dose modifications established; renal excretion is minimal (<1%), so no adjustment expected. |
| Liver impairment | No specific Child-Pugh based modifications established; hepatic metabolism is limited, but caution in severe impairment due to lack of data. |
| Pediatric use | Not studied; safety and efficacy in pediatric patients not established. |
| Geriatric use | No specific dose adjustment required; clinical trials included patients up to age 85; monitor for infusion-related reactions and amyloid-related imaging abnormalities (ARIA). |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for KISUNLA (KISUNLA).
| Breastfeeding | Unknown if distributed in human milk; endogenous IgG is present. M/P ratio not available. Consider developmental and health benefits of breastfeeding along with maternal clinical need. |
| Teratogenic Risk | Kisunla (donanemab) is an amyloid beta-directed monoclonal antibody. No animal reproduction studies have been conducted. In humans, IgG antibodies cross the placenta with increasing transfer in the second and third trimesters; potential fetal risks include immune-mediated toxicities. Use only if maternal benefit outweighs fetal risk. |
■ FDA Black Box Warning
WARNING: AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA). Donanemab can cause ARIA, including ARIA-E (edema/effusion) and ARIA-H (hemorrhage/hemosiderin deposition), which may be severe and life-threatening. ARIA typically occurs early in treatment and may resolve with discontinuation. Enhanced clinical vigilance and MRI monitoring are required.
| Serious Effects |
["Known serious hypersensitivity to donanemab or any excipients of Kisunla"]
| Precautions | ["Amyloid-related imaging abnormalities (ARIA), including ARIA-E and ARIA-H","Infusion-related reactions (e.g., chills, fever, headache)","Risk of intracerebral hemorrhage, especially in patients on anticoagulants","Hypersensitivity reactions including angioedema","Need for baseline and periodic MRI monitoring for ARIA"] |
Loading safety data…
| Fetal Monitoring |
| Monitor for infusion-related reactions, amyloid-related imaging abnormalities (ARIA) including ARIA-E and ARIA-H on MRI; pregnancy status should be confirmed prior to initiation and periodically. |
| Fertility Effects | No human fertility data; animal studies not conducted. No known impact on fertility based on mechanism of action. |